Gordon syndrome

Gordon syndrome, also known as distal arthrogryposis type 3 (DA3) or camptodactyly-cleft palate-clubfoot syndrome, is a rare genetic disorder classified among the distal arthrogryposes — a group of conditions characterized by congenital joint contractures primarily affecting the hands and feet. The condition was first described by Gordon and colleagues in 1969. Key clinical features include camptodactyly (permanent flexion contractures of the fingers, particularly the interphalangeal joints), talipes equinovarus (clubfoot), and cleft palate. Additional findings may include short stature, kyphoscoliosis, and cryptorchidism in males. The musculoskeletal system is primarily affected, though the craniofacial structures are also involved due to the presence of cleft palate. Gordon syndrome follows an autosomal dominant inheritance pattern with variable expressivity, meaning that affected individuals within the same family may show different combinations and severity of features. The condition is caused by mutations in genes involved in the contractile apparatus of muscle fibers, particularly the PIEZO2 gene, which has been implicated in several distal arthrogryposis subtypes. Diagnosis is based on clinical findings and can be confirmed through molecular genetic testing. Treatment is symptomatic and supportive. Orthopedic interventions, including serial casting, physical therapy, and surgical correction, may be employed for clubfoot and joint contractures. Cleft palate requires surgical repair, typically in infancy, along with speech therapy and dental follow-up. Early intervention with occupational therapy can help maximize hand function. Genetic counseling is recommended for affected families. While there is no cure, many individuals with Gordon syndrome can achieve good functional outcomes with appropriate multidisciplinary management.

Common questions about Gordon syndrome